- "AVIEW Report Ushers in a New Paradigm of Early Detection–Centered Health Screening"
- Showcased at the 2025 Annual Fall Conference of the Korean Society of Health Screening, with differentiated 3D visualization and quantitative analysis
- Adopted by leading screening centers including GC i-Med, enhancing communication between physicians and patients
- Minimizes radiation exposure while enabling comprehensive heart–lung diagnosis, opening the era of proactive health management
Seoul, August 26, 2025 – Coreline Soft, a leading medical AI company, announced that it will unveil its newly launched AVIEW Premium Diagnostic Report at the 2025 Fall Conference and Ultrasound Training of the Korean Society of Health Screening, to be held on August 31 at the SC Convention Center. The launch signals a significant transformation in the health screening market.
The Korean Society of Health Screening’s annual conference is a key academic event where nationwide health screening institutions and medical experts gather. Through its participation, Coreline Soft will demonstrate how its AI-based integrated screening system can set a new standard for premium health screening.
The AVIEW Premium Report is a next-generation screening tool designed for early detection, capable of providing a comprehensive assessment of both lung and cardiovascular disease risk with a single low-dose CT scan. Unlike conventional text-only radiology reports, AVIEW presents lesion locations and conditions in 3D visualization, supported by an intuitive UI/UX that allows individuals to better understand their health status and actively participate in their own care.
For individuals, the report minimizes radiation exposure while enabling simultaneous evaluation of pulmonary and coronary conditions, supported by an AI-powered automated analysis. For screening centers, it enhances clinical decision-making by providing previously hard-to-capture insights, offers competitive analytical results, supports population-level lung disease management, and creates new revenue opportunities through AI-driven reporting. The report has already been adopted by major health screening centers, including GC i-Med, accelerating its market penetration.
Dr. Sang-Man Kim, CEO of GC i-Med, commented: “With the adoption of AVIEW, both our Gangnam and Gangbuk centers can consistently deliver premium AI-assisted chest screening services, improving accessibility and convenience for examinees. We will continue to leverage AI to provide a highly reliable screening experience for both patients and clinicians.”
Jin-Kook Kim, CEO of Coreline Soft, added: “The AVIEW Premium Report represents a major step forward, expanding beyond hospital-based diagnostic support to become an early detection–centered premium screening tool accessible to the general public. It enables comprehensive evaluation of the heart and lungs while minimizing radiation exposure, thereby enhancing efficiency, safety, and ultimately contributing to public health improvement.”
Coreline Soft is actively expanding into international markets, including Europe and the U.S., and is recognized for its role in advancing global lung cancer screening through collaborations with hospitals worldwide. With the launch of the Premium Report, the company aims to further solidify its leadership in the domestic screening market while securing differentiated competitiveness in the global arena.
August 26, 2025
List